MedTrace Logo

Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)

NCT04949009 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-07-02

No results posted yet for this study

Summary

The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. Aims at evaluating effectiveness and safety of avatrombopag in the treatment of primary immune thrombocytopenia.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

DRUG

Avatrombopag

Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Ming Hou, MD PhD · Shandong University Qilu Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-10-01
Completion
2022-03-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04949009 on ClinicalTrials.gov